In the June podcast for The Journal of Community and Supportive Oncology, Dr David Henry discusses the approval of alectinib as a new option for ALK-positive patients with NSCLC who have progressed on crizotinib, and a How We Do It article in which the authors the implementation of ipilimumab therapy in a private practice oncology group. The authors describe how they addressed start-up and reimbursement issues related to ipilimumab as a model for other expensive new cancer drugs as well. Also included are research articles on long-term community-based results of breast-conserving therapy in early-stage breast cancer, the use of the neurokinin 1 receptor antagonist in moderately emetogenic chemotherapy, risk assessment for hereditary breast and ovarian cancer in minority women, the impact of a nurse practitioner-led symptom clinic on emergency department use in cancer patients, and assessing outpatient oncology needs. Finally, Dr Henry examines evolving therapeutic strategies in melanoma.
Listen to the podcast below.